ABSTRACT
Objetivo: El estudio CADIT-CAM es un estudio retrospectivo diseñado para analizar las características clínicas, el tratamiento y los resultados finales de los pacientes con cáncer diferenciado de tiroides (CDT) en Castilla-La Mancha. Pacientes y métodos: Se ha incluido a 1.434 pacientes diagnosticados en 7 hospitales castellano-manchegos, entre 2001 y 2015. Resultados: El 77% eran mujeres, con una edad media al diagnóstico de 48 años, y el tipo histológico principal fue carcinoma papilar en el 93%. El tamaño el tumor fue descendiendo de forma significativa a lo largo de los 15 años (p <0,05). El tratamiento con radioyodo se ha utilizado en el 84% de la serie, habiendo disminuido su utilización a lo largo del estudio, sobre todo en los de bajo riesgo de recurrencia. Existió recurrencia en el 22% de los pacientes, siendo los factores relacionados con la misma: sexo masculino, mayor tamaño tumoral, multifocalidad, presencia de metástasis linfáticas o a distancia o de afectación extratiroidea así como la presencia de anticuerpos antitiroglobulina con evolución desfavorable. Al final del seguimiento, el 76,2% de los casos estaban libres de enfermedad y el 2,4% de los pacientes habían fallecido por CDT, siendo la supervivencia global de la cohorte del 95,1% a los 15 años de seguimiento. Conclusiones: Las características del CDT de la cohorte de Castilla-La Mancha son similares a las de otras series españolas. Los resultados finales son excelentes y las tendencias del tratamiento se han ido adaptando al riesgo de recurrencia de los pacientes
Objective: The CADIT-CAM study was designed to retrospectively analyze the clinical characteristics, treatments, and outcomes of patients with differentiated thyroid carcinoma (DTC) in Castilla La Mancha. Patients and methods: A total of 1434 patients from 7 hospitals in Castilla La Mancha were enrolled into the study from 2001 to 2015. Results: Seventy-seven percent of patients were female, with a mean age at diagnosis of 48 years. Papillary thyroid carcinoma accounted for 93% of cases. Mean tumor size was significantly smaller at final follow-up (P<.05). Radioiodine ablation (RA) was performed in 84% of patients, and its use decreased during the study, especially in tumors with low recurrence risk. Recurrence occurred in 22% of patients and was associated to male gender, greater tumor size, multifocality, lymph node metastases, extrathyroid involvement, distant metastases and increasing thyroglobulin antibody titers. At the end of follow-up 76.2% of patients were alive and free of disease, 2.4% had died from DTC. Overall survival of the cohort was 95.1% at 15 years of follow-up. Conclusions: Characteristics of DTC in this Spanish cohort are similar to those reported in other studies in our country. Final results were excellent and use of treatment (RA) was consistent with risk-stratified recommendations
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Follow-Up Studies , Liposarcoma/diagnosis , Liposarcoma/therapy , Retrospective Studies , Thyroid Neoplasms/diagnosis , Thyroid Neoplasms/therapy , Spain , Neoplasm Recurrence, LocalABSTRACT
OBJECTIVE: The CADIT-CAM study was designed to retrospectively analyze the clinical characteristics, treatments, and outcomes of patients with differentiated thyroid carcinoma (DTC) in Castilla La Mancha. PATIENTS AND METHODS: A total of 1434 patients from 7 hospitals in Castilla La Mancha were enrolled into the study from 2001 to 2015. RESULTS: Seventy-seven percent of patients were female, with a mean age at diagnosis of 48 years. Papillary thyroid carcinoma accounted for 93% of cases. Mean tumor size was significantly smaller at final follow-up (P<.05). Radioiodine ablation (RA) was performed in 84% of patients, and its use decreased during the study, especially in tumors with low recurrence risk. Recurrence occurred in 22% of patients and was associated to male gender, greater tumor size, multifocality, lymph node metastases, extrathyroid involvement, distant metastases and increasing thyroglobulin antibody titers. At the end of follow-up 76.2% of patients were alive and free of disease, 2.4% had died from DTC. Overall survival of the cohort was 95.1% at 15 years of follow-up. CONCLUSIONS: Characteristics of DTC in this Spanish cohort are similar to those reported in other studies in our country. Final results were excellent and use of treatment (RA) was consistent with risk-stratified recommendations.
